Genus plc produces and sells animal genetics to farmers in North America, Latin America, the United Kingdom, the rest of Europe, the Middle East, Russia, Africa, and Asia. The company operates through three segments: Gen…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Yesterday | ||
Older | ||
How Genus (LSE:GNS) Narrative Is Shifting As Analysts Recalibrate Valuation Assumptions Genus has seen its modelled fair value move from £30.82 to £31.67, a small uplift that may still matter if you are tracking the shares closely. Analysts linking this £1.00 change to revised assumptions are effectively updating how they weigh Genus’ potential against execution risks, with bullish and cautious camps reading the same inputs in different ways. As you read on, you will see how these shifts fit into the broader analyst debate and what to watch as the narrative evolves. Analyst... | ||
Genus PLC (GENSF) (Q1 2026) Earnings Call Highlights: Record Profit and Strategic Growth Initiatives Genus PLC (GENSF) reports a 57% increase in profit before tax, driven by strong PIC performance and strategic ventures in China. | ||
Genus H1 Earnings Call Highlights Genus (LON:GNS) reported a strong first-half performance for FY 2026, delivering record first-half profit as growth in its PIC porcine genetics business and ongoing margin work in its ABS bovine genetics unit outweighed a mixed market backdrop. Management also highlighted major strategic milestones, | ||
A Look At The Intrinsic Value Of Genus plc (LON:GNS) Key Insights Genus' estimated fair value is UK£31.90 based on 2 Stage Free Cash Flow to Equity With UK£29.70 share... | ||
Trending tickers: Morgan Stanley, Anglo American, Genus and BAE Systems The wealth management unit posted $8.4bn in net revenue in the most recent quarter, up from $7.5bn a year earlier. | ||
Investing in Genus (LON:GNS) a year ago would have delivered you a 71% gain The simplest way to invest in stocks is to buy exchange traded funds. But investors can boost returns by picking... | ||
Why The Narrative Around Genus Is Shifting As Gene Editing Expectations Rise Genus has seen a slight uplift in its fair value estimate to about £29.81 per share, even as long term revenue growth assumptions have been nudged lower and the discount rate edged higher. This reflects a more balanced view of risk and reward. These shifts capture rising analyst conviction that the company’s gene editing platform can deliver durable, above market earnings growth, while still acknowledging regulatory and execution uncertainties. Stay tuned to learn how you can track these... | ||
What Developments Are Shaping the New Narrative for Genus? Genus stock has received a modest upward revision to its fair value estimate, increasing from £27.97 to £29.72. This adjustment reflects renewed analyst confidence, as well as cautious optimism about the company’s ability to deliver consistent performance in its key markets. Stay tuned to learn how you can follow the evolving story behind these adjustments and stay informed about future valuation updates. Stay updated as the Fair Value for Genus shifts by adding it to your watchlist or... | ||
3 UK Stocks That May Be Trading At Discounts Of Up To 43.6% The UK stock market has recently faced challenges, with the FTSE 100 index experiencing declines due to weak trade data from China, highlighting the interconnectedness of global economies. As London's bluechip index falters, investors may find opportunities in undervalued stocks that could potentially offer value despite broader market uncertainties. | ||